Valneva SE (INRLF)
OTC
Closed
Aug 24, 2026
Day's Range
3.2952 wk Range
2.43Overview - INRLF - Valneva SE
Key Statistics
Valuation
Enterprise Value
832.03M
P/E (Trailing)
‪68.89‬
PEG Ratio
‪0.34‬
Price / Sales (TTM)
‪4.36‬
Price / Book
‪6.57‬
EV / EBITDA
‪-7.21‬
Profitability
Gross Margin
‪15.28%‬
Profit Margin
‪-110.29%‬
Operating Margin
‪-74.91%‬
Return on Assets
‪-16.68%‬
Return on Equity
‪-117.84%‬
Ownership
Shares Outstanding
173.75M
Float
157.26M
Held by Insiders
‪10.72%‬
Held by Institutions
‪24.41%‬
Price stats
Beta
‪1.34‬
50-Day Avg
‪2.66‬
200-Day Avg
‪3.66‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - INRLF - Valneva SE
Peer Comparison
Compared with companies in Biotechnology listed on OTC.
Profile Summary - INRLF - Valneva SE
About
Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France, that develops, manufactures, and commercializes prophylactic vaccines targeting infectious diseases with significant unmet medical needs. Its commercial portfolio features three key vaccines: IXIARO®, for Japanese encephalitis;…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
